Key Inclusion Criteria:

        Histological or cytological diagnosis of advanced / metastatic solid tumor with the
        following tumor types in individual study parts:

        Part 1A:

        -Histologically / cytologically confirmed advanced/unresectable or metastatic SCLC, CRPC,
        DLBCL and FL that is refractory to or intolerable of standard treatment, or for which no
        curative treatment is available. Note for FL (Parts 1A and 1B) during the dose finding
        phase of study, follicular lymphoma patients must have exhausted all standard of care
        therapies.

        Part 1B:

        Histologically confirmed FL patients that have exhausted all curative therapies and have
        relapsed or refractory disease.

        Part 2:

          -  Histologically or cytologically confirmed treatment naïve extensive disease SCLC
             patients;

          -  Histologically confirmed FL patients that are intolerant of or resistant to standard
             therapy or for which no curative therapy is available and have relapsed or refractory
             disease (Part 2B).

          -  Histological / cytological diagnosis of castration resistant prostate cancer. Received
             either abiraterone and/or enzalutamide treatment and has evidence of prostate cancer
             progression (per PWG3):

               -  SCLC patients entering the study in the expansion cohort with at least one
                  measurable lesion as defined by Response Evaluation Criteria in Solid Tumors
                  (RECIST) version 1.1.

               -  FL patients entering the study in the expansion cohort with at least one
                  measurable lesion as defined by Response Evaluation Criteria in Lymphoma (RECIL)
                  criteria.

               -  Females and/or male patients age 18 years.

               -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.

               -  Adequate Bone Marrow Function

               -  Adequate Renal Function

               -  Adequate Liver Function

               -  Serum pregnancy test (for females of childbearing potential) negative at
                  screening, and negative serum or urine pregnancy test at baseline prior to
                  treatment administration.

        Exclusion Criteria:

          -  Known symptomatic brain metastases requiring steroids or CNS involvement in FL.
             Previously diagnosed brain metastases are eligible if they have been treated and
             recovered from the acute effects of radiation therapy or surgery prior to study entry,
             have discontinued corticosteroid treatment for these metastases for at least 4 weeks
             and are neurologically stable. Physiologic replacement doses of corticosteroids are
             permissible.

          -  At least 3 weeks since last major surgery (a lesser period is acceptable if decided to
             be in the best interest of the SCLC patient).

          -  Treatment with more than 2gm acetaminophen per day within 14 days of study entry and
             on study if required.

          -  Chronic liver diseases.

          -  History of alcohol abuse or binge drinking in the last 6 months prior to screening.

          -  Radiation therapy within 4 weeks prior to study entry. Note, patients who have
             received radiotherapy must have recovered from any reversible side effects, such as
             nausea and vomiting.

          -  Systemic anti cancer therapy - approved or investigational - within 4 weeks or 5
             half-lives, whichever is shorter, prior to study entry, including antibody based
             agents. Prostate cancer cohorts 2A and 2B must have not received more than 1 previous
             regimen of systemic chemotherapy in mCPRC setting. SCLC cohorts must be chemotherapy
             naive for SCLC however may have received one cycle of chemotherapy after discussion
             with the sponsor.

          -  Last anti hormonal therapy within 2 weeks prior to C1D1.

          -  Prior stem cell transplant, autologous or allogenic, within 100 days prior to study
             enrollment or patients who experienced graft veses host disease or who require
             systemic immune suppressive therapy.

          -  Prior irradiation to >25% of the bone marrow.

          -  Active and clinically significant bacterial, fungal, or viral infection, including
             hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus
             (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.

          -  Any of the following in the previous 6 months: myocardial infarction, congenital long
             QT syndrome, Torsades de pointes, arrhythmias (including sustained ventricular
             tachyarrhythmia and ventricular fibrillation), right bundle branch block and left
             anterior hemiblock (bifascicular block), unstable angina, coronary/peripheral artery
             bypass graft, symptomatic congestive heart failure (New York Heart Association class
             III or IV), cerebrovascular accident, transient ischemic attack, or symptomatic
             pulmonary embolism; ongoing cardiac dysrhythmias of NCI CTCAE Grade 2, atrial
             fibrillation of any grade, or QTcF interval >480 msec at screening.

          -  Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal
             medical therapy).

          -  Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide
             (CRPC) or platinum compound.

          -  Other acute or chronic medical or psychiatric condition, including recent (within the
             past year) or active suicidal ideation or behavior or laboratory abnormality that may
             increase the risk associated with study participation or investigational product
             administration or may interfere with the interpretation of study results and, in the
             judgment of the investigator, would make the patient inappropriate for entry into this
             study.

          -  Investigator site staff members directly involved in the conduct of the study and
             their family members, site staff members otherwise supervised by the investigator, or
             patients who are Pfizer employees, including their family members, directly involved
             in the conduct of the study.

          -  Pregnant female patients; breastfeeding female patients; fertile male patients and
             female patients of childbearing potential who are unwilling or unable to use 2 highly
             effective methods of contraception as outlined in this protocol for the duration of
             the study and for at least 28days after the last dose of investigational product.

          -  Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular
             disease or previous gastric resection or lap band surgery. Gastroesophageal reflux
             disease under treatment with proton pump inhibitors is allowed.

          -  Current use or anticipated need for food or drugs that are known strong CYP3A4/5
             inhibitors, including their administration within 10 days or 5 half lives of the
             CYP3A4/5 inhibitor, whichever is longer prior to first dose of investigational
             product.

          -  Current use or anticipated need for drugs that are known strong CYP3A4/5 inducers,
             including their administration within 10 days or 5 half lives of the CYP3A4/5 inducer,
             whichever is longer prior to the first dose of investigational product.